Multiple Sclerosis Treatment Becomes Canada’s First MS Stem Cell Clinical Trial.

The University of Ottawa trial infuses MSCs to reduce inflammation in the central nervous systems of MS patients.

The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients. Continue reading

Multiple Sclerosis Trial Exhibits Positive Results of Stem Cell Therapy.

A five year phase II clinical trial has shown initial success in treating multiple sclerosis.

In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations.  The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission. Continue reading

Multiple Sclerosis Therapy Incorporates Stem Cells in Clinical Trial

Mesenchymal Stem Cell Therapy has been deemed safe for patients suffering from multiple sclerosis.

A recent clinical trial conducted by the University of Genoa has determined that mesenchymal stem cell therapy to treat multiple sclerosis is indeed safe to perform on humans.  27 MS patients completed the study, which comprised an injection of the patient’s own [autologous] mesenchymal stem cells [MSCs] to reduce excessive inflammation caused by the patients’ own immune systems. None of the patients suffered any side effects from the injection. Continue reading

Multiple Sclerosis Therapy Incorporates Stem Cells in Clinical Trial

Mesenchymal Stem Cell Therapy has been deemed safe for patients suffering from multiple sclerosis.

A recent clinical trial conducted by the University of Genoa has determined that mesenchymal stem cell therapy to treat multiple sclerosis is indeed safe to perform on humans.  27 MS patients completed the study, which comprised an injection of the patient’s own [autologous] mesenchymal stem cells [MSCs] to reduce excessive inflammation caused by the patients’ own immune systems. None of the patients suffered any side effects from the injection. Continue reading

Of Mice and Men: Human Stem Cells Utilized in Animal Model Treatment of MS Symptoms

Advancements in a breakthrough stem cell study may provide new treatment options for MS patients.

A team of researchers led by Professor Jeanne Loring of the Scripps Research Institute have advanced a potential treatment option for autoimmune diseases similar to multiple sclerosis by utilizing human stem cells to reregulate the immune system. In an animal model paralyzed by MS symptoms, the scientists differentiated human stem cells into early stage neural cells that, when transplanted into the spinal cords of the compromised mice, secreted proteins that halted the autoimmune attack and enabled the mice to walk and run again. Continue reading

Multiple Sclerosis Patients Reboot Immune System with Stem Cells

Biologists have successfully reset the self-destructive immune systems of Multiple Sclerosis patients by utilizing autologous stem cells.

In a recent publication, biologists in the Immune Tolerance Network have used autologous [the patient’s own] stem cells to refurbish the immune systems of Multiple Sclerosis [MS] patients to no longer favor autoimmunity. The ITN researchers suppressed the patients’ immune systems, transplanted the stem cells, and in a 12 month follow-up, identified key distinctions between the patients’ T-cells before and after the transplant, indicating that the procedure was a success. Continue reading

Wall Street Journal Reports on Stem Cells in Umbilical Cord Blood

Saving stem cells in cord blood ensures access to emerging regenerative therapies.

As reported by the Wall Street Journal, adult stem cell therapies are advancing rapidly; with researchers utilizing stem cells to treat an expanding range of disease, trauma and injury.  The article highlights the increasing use of cord blood to treat a variety of ailments such as; Cerebral Palsy, Traumatic Brain Injury and immune deficiencies such as diabetes. Continue reading

Stem Cell Advance Gives Hope for Neurodegenerative Treatment

neuron

 

 

 

 

 

 

Scientists in the US (UC, UCSD) and China (Wuhan) have found a way to convert stem cells into functional neurons. The researchers were able to suppress an RNA-binding protein, inducing the stem cells to become neurons. This gives hope for a treatment for neurodegenerative diseases such as Huntington’s, Parkinson’s, Alzheimer’s, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), which will afflict one in four Americans over their lifetime.

Continue reading

Australia and United States Collaborate on Stem Cell Research to Treat Multiple Sclerosis

In another example of how regenerative medicine is reshaping the research community through international collaborations, researchers at Monash University and Melbourne’s CSIRO in Australia are collaborating with the University of California on a new stem cell therapy aimed at treating multiple sclerosis, a degenerative disease of the central nervous system that previously had no cure.

Continue reading